Literature DB >> 11510622

Stiff man syndrome.

H M Meinck1.   

Abstract

Stiff man syndrome (SMS), an uncommon neurological disease, is characterised by symmetrical muscle stiffness and spasms that often lead to skeletal deformity. Variants of the syndrome may involve one limb only (stiff leg syndrome), a variety of additional neurological symptoms and signs such as eye movement disturbances, ataxia, or Babinski signs (progressive encephalomyelitis with rigidity and myoclonus), or be associated with malignant disease (paraneoplastic SMS). Antineuronal autoimmunity and accompanying autoimmune diseases, most often insulin-dependent diabetes mellitus, are characteristic features of SMS and its variants. The condition is frequently misinterpreted as psychogenic movement disturbance, but electromyographic abnormalities and the presence of autoantibodies against glutamic acid decarboxylase (GAD) in both serum and cerebrospinal fluid help to establish the correct diagnosis. The aetiology of SMS is obscure. However, several features suggest that SMS is an autoimmune-mediated chronic encephalomyelitis. In line with this hypothesis, immunomodulation with a front-loaded methylprednisolone regimen reduces stiffness and spasms and improves other neurological symptoms in the majority of patients. Plasmapheresis or intravenous immunoglobulins are effective less frequently. For symptomatic treatment, the benzodiazepines are drugs of first choice. An alternative of last resort is baclofen administered intrathecally via an implanted pump device.

Entities:  

Mesh:

Year:  2001        PMID: 11510622     DOI: 10.2165/00023210-200115070-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  40 in total

Review 1.  [Stiff-man syndrome from neurological perspective].

Authors:  H M Meinck
Journal:  Internist (Berl)       Date:  2000-05       Impact factor: 0.743

2.  Autoimmunity to gephyrin in Stiff-Man syndrome.

Authors:  M H Butler; A Hayashi; N Ohkoshi; C Villmann; C M Becker; G Feng; P De Camilli; M Solimena
Journal:  Neuron       Date:  2000-05       Impact factor: 17.173

Review 3.  A critical survey of stiff-man syndrome.

Authors:  E E Gordon; D M Januszko; L Kaufman
Journal:  Am J Med       Date:  1967-04       Impact factor: 4.965

Review 4.  Stiff muscles.

Authors:  P D Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

5.  Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.

Authors:  A Saiz; J Arpa; A Sagasta; R Casamitjana; J J Zarranz; E Tolosa; F Graus
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

6.  Stiff man syndrome: neurophysiological findings in eight patients.

Authors:  H M Meinck; K Ricker; P J Hülser; M Solimena
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

Review 7.  Stiff-man syndrome updated.

Authors:  T R Lorish; G Thorsteinsson; F M Howard
Journal:  Mayo Clin Proc       Date:  1989-06       Impact factor: 7.616

8.  Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome.

Authors:  K Dinkel; H M Meinck; K M Jury; W Karges; W Richter
Journal:  Ann Neurol       Date:  1998-08       Impact factor: 10.422

9.  Treatment of stiff-man syndrome with intravenous immunoglobulin.

Authors:  A A Amato; E W Cornman; J T Kissel
Journal:  Neurology       Date:  1994-09       Impact factor: 9.910

10.  [The stiff-man syndrome. A case report with regard to clinical, electromyographical and pharmacological signs (author's transl)].

Authors:  M Stöhr; R Heckl
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1977-02-23
View more
  7 in total

1.  Treatment of paraneoplastic neurologic disorders.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

2.  Anti-GAD antibody positive stiff-limb syndrome in multiple myeloma.

Authors:  David Schiff; Josep Dalmau; Delynne J Myers
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

3.  The effect of clinical pilates-based physiotherapy program for a Stiff Person Syndrome patient: a case report.

Authors:  Beliz Belgen Kaygisiz; Fahriye Çoban; Ferda Selcuk
Journal:  Acta Neurol Belg       Date:  2020-09-30       Impact factor: 2.396

Review 4.  GAD antibodies in neurological disorders - insights and challenges.

Authors:  Francesc Graus; Albert Saiz; Josep Dalmau
Journal:  Nat Rev Neurol       Date:  2020-05-26       Impact factor: 42.937

Review 5.  Anti-glutamic acid decarboxylase antibody positive neurological syndromes.

Authors:  Hassaan Tohid
Journal:  Neurosciences (Riyadh)       Date:  2016-07       Impact factor: 0.906

6.  Anti-glutamic acid decarboxylase antibody (GAD) syndromes may have more aggressive disease course in African Americans and early onset of presentation compare to Caucasians group.

Authors:  Shitiz Sriwastava; Meghana Srinivas; Anila Kanna; Kalyan Yarraguntla; Abbas Jowkar; Edwin George
Journal:  eNeurologicalSci       Date:  2019-09-11

7.  High-Yield Production in Escherichia coli of Fungal Immunomodulatory Protein Isolated from Flammulina velutipes and Its Bioactivity Assay in Vivo.

Authors:  Xianghui Kong; Jiechi Zhang; Xue Han; Piqi Zhang; Xiaodong Dai; Jianing Liu; Xinxin Zhang; Imshik Lee; Shenkui Liu
Journal:  Int J Mol Sci       Date:  2013-01-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.